Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective
Bisphosphonates (BPs) are an important class of drugs, useful in the treatment of some metabolic and oncologic skeletal diseases. BPs have shown a sure effectiveness in the treatment and in the palliative care of such pathologies; on the other hand, an avascular osteonecrosis of the jaws (B-ONJ = Bi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2012-01-01
|
| Series: | European Journal of Inflammation |
| Online Access: | https://doi.org/10.1177/1721727X1201000102 |
| _version_ | 1828879534049460224 |
|---|---|
| author | G. Pompa I. Bignozzi M.P. Cristalli A. Quaranta S. Di Carlo S. Annibali |
| author_facet | G. Pompa I. Bignozzi M.P. Cristalli A. Quaranta S. Di Carlo S. Annibali |
| author_sort | G. Pompa |
| collection | DOAJ |
| description | Bisphosphonates (BPs) are an important class of drugs, useful in the treatment of some metabolic and oncologic skeletal diseases. BPs have shown a sure effectiveness in the treatment and in the palliative care of such pathologies; on the other hand, an avascular osteonecrosis of the jaws (B-ONJ = Bisphosphonate OsteoNecrosis of the Jaw) has recently been reported as an adverse effect not only of BP intravenous infusions, but also of their prolonged oral administration. B-ONJ normally follows a dental extraction or other surgical procedure in the oral cavity, but it also can develop spontaneously. In the latter case, some systemic risk factors, such as comorbidities and co-therapies or jaw anatomical conditions, can play a leading role in the onset of this pathologic condition. B-ONJ is an uncommon but potentially serious complication of BP therapy that can gravely affect the patient's quality of life, producing significant morbidity. To date, no therapies are completely effective and predictable in the treatment of B-ONJ, therefore prevention should be strongly promoted by sharing knowledge in the involved medical community. |
| first_indexed | 2024-12-13T09:29:05Z |
| format | Article |
| id | doaj.art-35ec1d7620b24be3815a5c571b7d8f23 |
| institution | Directory Open Access Journal |
| issn | 1721-727X |
| language | English |
| last_indexed | 2024-12-13T09:29:05Z |
| publishDate | 2012-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | European Journal of Inflammation |
| spelling | doaj.art-35ec1d7620b24be3815a5c571b7d8f232022-12-21T23:52:32ZengSAGE PublishingEuropean Journal of Inflammation1721-727X2012-01-011010.1177/1721727X1201000102Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's PerspectiveG. Pompa0I. Bignozzi1M.P. Cristalli2A. Quaranta3S. Di Carlo4S. Annibali5 Department of Oral and Maxillofacial Sciences, Prosthodontics Unit, “Sapienza” University of Rome, Rome Department of Oral and Maxillofacial Sciences, Oral Surgery Unit, “Sapienza” University of Rome, Rome Department of Oral and Maxillofacial Sciences, Oral Surgery Unit, “Sapienza” University of Rome, Rome Department of Clinical and Odontostomatological Sciences, Periodontics Unit, Polytechnic University of the Marche, Ancona, Italy Department of Oral and Maxillofacial Sciences, Prosthodontics Unit, “Sapienza” University of Rome, Rome Department of Oral and Maxillofacial Sciences, Oral Surgery Unit, “Sapienza” University of Rome, RomeBisphosphonates (BPs) are an important class of drugs, useful in the treatment of some metabolic and oncologic skeletal diseases. BPs have shown a sure effectiveness in the treatment and in the palliative care of such pathologies; on the other hand, an avascular osteonecrosis of the jaws (B-ONJ = Bisphosphonate OsteoNecrosis of the Jaw) has recently been reported as an adverse effect not only of BP intravenous infusions, but also of their prolonged oral administration. B-ONJ normally follows a dental extraction or other surgical procedure in the oral cavity, but it also can develop spontaneously. In the latter case, some systemic risk factors, such as comorbidities and co-therapies or jaw anatomical conditions, can play a leading role in the onset of this pathologic condition. B-ONJ is an uncommon but potentially serious complication of BP therapy that can gravely affect the patient's quality of life, producing significant morbidity. To date, no therapies are completely effective and predictable in the treatment of B-ONJ, therefore prevention should be strongly promoted by sharing knowledge in the involved medical community.https://doi.org/10.1177/1721727X1201000102 |
| spellingShingle | G. Pompa I. Bignozzi M.P. Cristalli A. Quaranta S. Di Carlo S. Annibali Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective European Journal of Inflammation |
| title | Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective |
| title_full | Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective |
| title_fullStr | Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective |
| title_full_unstemmed | Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective |
| title_short | Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective |
| title_sort | bisphosphonate and osteonecrosis of the jaw the oral surgeon s perspective |
| url | https://doi.org/10.1177/1721727X1201000102 |
| work_keys_str_mv | AT gpompa bisphosphonateandosteonecrosisofthejawtheoralsurgeonsperspective AT ibignozzi bisphosphonateandosteonecrosisofthejawtheoralsurgeonsperspective AT mpcristalli bisphosphonateandosteonecrosisofthejawtheoralsurgeonsperspective AT aquaranta bisphosphonateandosteonecrosisofthejawtheoralsurgeonsperspective AT sdicarlo bisphosphonateandosteonecrosisofthejawtheoralsurgeonsperspective AT sannibali bisphosphonateandosteonecrosisofthejawtheoralsurgeonsperspective |